Systematic safety evaluation on photoluminescent carbon dots

Kan Wang¹, Zhongcai Gao², Guo Gao¹, Yan Wo¹, Yuxia Wang²*, Guangxia Shen¹* and Daxiang Cui¹*

Abstract
Photoluminescent carbon dots (C-dots) were prepared using the improved nitric acid oxidation method. The C-dots were characterized by tapping-mode atomic force microscopy, and UV–vis absorption spectroscopy. The C-dots were subjected to systematic safety evaluation via acute toxicity, subacute toxicity, and genotoxicity experiments (including mouse bone marrow micronuclear test and Salmonella typhimurium mutagenicity test). The results showed that the C-dots were successfully prepared with good stability, high dispersibility, and water solubility. At all studied C-dot dosages, no significant toxic effect, i.e., no abnormality or lesion, was observed in the organs of the animals. Therefore, the C-dots are non-toxic to mice under any dose and have potential use in fluorescence imaging in vivo, tumor cell tracking, and others.

Keywords: Carbon dots, Biocompatibility, Toxicity

Background
The importance of fluorescent nanoprobes in biomedical research and practice is rapidly increasing with the rapid developments in fluorescence microscopy, laser technologies, and nanotechnology. Fluorescent carbon dots (C-dots), a novel form of nanocarbon, have the inherent properties of traditional semiconductor-based quantum dots (e.g., size- and wavelength-dependent luminescence emissions, resistance to photobleaching, and ease of bioconjugation). Apart from these properties, C-dots also possess special features such as physicochemical stability, photochemical stability, and non-blinking behavior [1-3]. The preparation methods of C-dots are relatively simple, low cost, and applicable in large scales. Numerous approaches for synthesizing C-dots have been proposed, including dry methods (arc discharge [4,5] and laser ablation [6]) and solution methods (combustion/thermal [7-9], electrochemical oxidation [10], organic synthesis [11], and microwave methods [12-14]). C-dots are also potential replacements for conventional cadmium-based quantum dots used in biological imaging in vitro and in vivo [6,15-22] and have attracted significant attention since the pioneering work of Sun et al. [20,21].

Although carbon is not considered as an intrinsically toxic element, the specific material configurations and structures of C-dots may be potential risks to human health, thereby raising public concern [22]. Many toxicity evaluations have been conducted for various carbon nanomaterials in recent years, and the results of the different methods are discrepant [23-34]. The current work aimed to study systematically the toxicity of C-dot solution exposure in rats and mice by biochemical and hematological analyses. C-dots are found to have the advantages of chemical inertness, low cytotoxicity, and good biocompatibility.

Main text
Materials and methods
Preparation and characterization of carbon nanodots
C-dots were prepared using the improved nitric acid oxidation method. In a typical experiment, 0.5 g of raw soot (purchased from Jixi Kaiwen Hu, Co., Ltd., Jixi, China) was placed in acetonitrile solution, ultrasonically cleaned for 30 min, centrifuged to discard the upper yellow solution, and then dried under a vacuum at 80°C. Subsequently, the cleaned soot was refluxed in 25 mL of 5 M HNO₃ at 120°C for 12 to 18 h until a homogeneous black aqueous
suspension was obtained. This black suspension was centrifuged at 3,000 rpm for 10 min to remove unreacted precipitates. The light-brown solution was collected, neutralized, and extensively dialyzed with an MWCO-1000 membrane against pure water. The suspended solution was precipitated by adding acetone and centrifuged at 14,000 rpm for 10 min. Size separation was performed in a water/ethanol/chloroform solvent mixture by high-speed (8,000 to 10,000 rpm) stepwise centrifugation. The supernatant was collected after spinning at 10,000 rpm, and the precipitate was discarded. Finally, a yellow solution of C-dots with 1- to 3-nm particle sizes was obtained. The C-dots were passivated with a PEG2000N solution at 140°C under the protection of nitrogen gas for 72 h. The dots were then dialyzed using an MCO 3000 dialysis membrane to remove excess PEG2000N.

Tapping-mode (TM)-atomic force microscopy (AFM) images of the C-dots -NH2 were taken using a MultiMode Nanoscope IIIa scanning probe microscopy system (Veeco Instruments Inc., Plainview, NY, USA). Commercially available AFM cantilever tips with a force constant of approximately 48 N/m and a resonance vibration frequency of approximately 330 kHz were used. The scanning rate was set to 1 to 1.5 Hz. The samples for TM-AFM were prepared by dropping an aqueous suspension (0.01 mg/mL) of C-dots NH2 on a freshly cleaved mica surface and drying under a vacuum at 80°C. UV–vis spectra were obtained at 20°C using a Shimadzu UV-2450 UV–vis spectrophotometer (Shimadzu Corporation, Kyoto, Japan) equipped with a 10-mm quartz cell and with a light path length of 1 cm. Fluorescence spectra were obtained using a Hitachi FL-4600 spectrofluorimeter (Hitachi Ltd., Tokyo, Japan).

**Experimental animals**

Systematic safety evaluation experiments (acute toxicity, subacute toxicity, and genotoxicity experiments, including mouse bone marrow micronuclear test and Salmonella typhimurium mutagenicity (Ames) test) were conducted. All animal experiments were performed in compliance with the local ethics committee. Animals were obtained from the animal laboratories of the Academy of Military Medical Sciences in compliance with the institutional Animal Care and Use Program Guidelines. The animals were given food and water, and housed under 12 h/12 h light/dark cycle. After acclimation, the animals were randomly divided into different groups for in vivo toxicity evaluations.

**Acute toxicity evaluations**

Sixty BALB/c mice (17 to 21 g) were divided into three groups of 20 each for tail injections to test for acute toxicity. Each group had 10 female and 10 male mice that were intravenously exposed to C-dots through a single tail injection of either 5.1 or 51 mg/kg body weight (BW). Other mice were injected with 0.9% NaCl aqueous solution to serve as the control group. Within 14 days of monitoring, the body weights of the mice were measured. At various time points (3 and 14 days after exposure), 10 mice (5 males and 5 females) per time point were sacrificed. Blood samples were collected from each mouse for blood chemistry tests and complete blood panel analysis. Statistical calculations were based on the standard deviations of 10 mice per group.

**Subacute toxicity evaluations**

Sixty-four Wistar rats (177 to 224 g) were randomly divided into three test groups (low, medium, or high dose) and one control group with 16 rats in each group (8 males and 8 females). The rats in the control group were exposed to 0.9% NaCl aqueous solution. At 1, 3, 7, and 28 days after exposure, blood from each group was collected and analyzed.

![Image 1](image.png)

**Figure 1** Image, analysis, and spectra of C-dots-NH2. (A) TM-AFM image of C-dots-NH2. (B) The section analysis selected the site in (A) labeled with a white line. (C) UV absorption and photoluminescence spectra of C-dots-NH2 in pure water, the inset of the photography excited at 302 nm with an 8-W UV light.
The extracts and controls were added to nutrient media inoculated with *S. typhimurium* (TA97, TA98, TA100, and TA102) with or without the S9 system (*in vitro* metabolic activation system using S9 mixture). The number of colonies in each culture dish was scored after 48 h of cell culture. The plates were divided into four groups: negative, positive, positive solvent, and test groups. The test group was added to C-dot media with final doses of 0.0125, 0.025, 0.05, and 0.1 mg/plate.

**Discussion**

**Characteristics of the C-dots**

The morphology and sectional analyses of C-dots-NH₂ were performed by TM-AFM, and the results are shown in Figure 1A, B, respectively. The C-dots were quasispherical and uniform, with diameters ranging from 1 to 3 nm. After grafting with PEG2000N, the nanoparticle sizes slightly increased to 3 to 5 nm. The UV–vis absorption and fluorescence emission spectra of C-dots-NH₂ are shown in Figure 1C. The peak and edge of the UV–vis spectra were at 320 and 450 nm, respectively. At an excitation wavelength of 370 nm, a strong emission peak at 540 nm was observed in the photoluminescence emission spectrum of C-dots-NH₂. In addition, we also added the (a) statistical sizes of C-dots and C-dots-NH₂ and (b) Zeta potential (see Additional file 1: Figure S1).

**Acute toxicity evaluations**

C-dot doses of 5.1 or 51 mg/kg BW did not cause mortality in the exposed mice, and no obvious clinical toxicity sign was observed. The female BALB/c mice treated with C-dots appeared healthy, and their body weight gain patterns were similar to those of the controls (*P* > 0.05) 3, 7, and 14 days after exposure. The male BALB/c mice treated with a high dose of the C-dots showed a significant difference from the control group 14 days after exposure. No significant difference was observed 3 and 7 days after exposure (*P* > 0.05), as shown in Table 1.

**Table 2** Biochemistry results of mice intravenously exposed to C-dots (day 3)

| Biochemical index               | Control (n = 10) | Low (n = 10) | High (n = 10) | F value | P value |
|---------------------------------|------------------|--------------|---------------|---------|---------|
| Glutamate-pyruvate transaminase | 40 ± 8           | 45 ± 15      | 43 ± 7        | 0.597   | 0.558   |
| (U/L)                           |                  |              |               |         |         |
| Glutamic oxaloacetic transaminase| 108 ± 22         | 111 ± 31     | 99 ± 15       | 0.697   | 0.507   |
| (U/L)                           |                  |              |               |         |         |
| Urea (mmol/L)                   | 8.08 ± 1.79      | 6.79 ± 1.10  | 7.13 ± 2.08   | 1.521   | 0.237   |
| Creatinine (μmol/L)             | 30 ± 2           | 28 ± 3       | 26 ± 2**      | 9.367   | 0.001   |
| Cholesterol (mmol/L)            | 2.82 ± 0.25      | 2.68 ± 0.30  | 2.80 ± 0.50   | 0.428   | 0.656   |
| Triglyceride (mmol/L)           | 1.39 ± 0.68      | 1.62 ± 0.56  | 1.44 ± 0.43   | 0.468   | 0.632   |
| Blood glucose (mmol/L)          | 8.40 ± 1.38      | 8.17 ± 1.08  | 7.50 ± 0.80   | 1.749   | 0.193   |
| Total protein (g/L)             | 528 ± 40         | 508 ± 26     | 510 ± 2.4     | 1.381   | 0.268   |
| Albumin (g/L)                   | 33.3 ± 3.0       | 32.0 ± 20    | 31.9 ± 2.2    | 1.147   | 0.333   |
After treatment with carbon dots, the body weight of the mouse was weighed at different time points after the administration. Data were mean ± SD. *P < 0.05 compared with control by one-way ANOVA test.

On the third day after exposure, no significant difference was found among all groups in terms of the glutamic oxaloacetic transaminase (GOT), glutamate pyruvate transaminase (GPT), urea, cholesterol, triacylglyceride (TG), blood glucose, total protein, and albumin levels (P > 0.05). In contrast, the creatinine (Cr) levels in the high-dose group showed significant differences (P < 0.01), as shown in Table 2.

The biochemical parameters of mice were determined 3 days after C-dot treatment. Data were mean ± SD. **P < 0.01 compared with that from mice in the control group by one-way ANOVA test.

On the 14th day after exposure, no significant difference was found among all groups in their levels of GOT, GPT, urea, Cr, cholesterol, TG, total protein, and albumin (P > 0.05). Blood glucose showed significant differences from the low-dose (P < 0.01) and high-dose (P < 0.05) groups compared with the control group (Table 3). The significant decrease in the blood glucose concentration may be associated with the long duration of anesthesia.

The biochemical parameters of mice were determined at 14 days after C-dot treatment. Data were mean ± SD. *P < 0.05, **P < 0.01 compared with that from mice in the control group by one-way ANOVA test.

### Table 3 Biochemistry results of mice intravenously exposed to C-dots (day 14)

| Biochemical index                  | Control (n = 10) | Low (n = 10) | High (n = 10) | F value | P value |
|-----------------------------------|-----------------|-------------|--------------|---------|---------|
| Glutamate-pyruvate transaminase (U/L) | 39 ± 11         | 41 ± 8      | 38 ± 8       | 0.352   | 0.707   |
| Glutamic oxaloacetic transaminase (U/L) | 104 ± 26        | 104 ± 20    | 94 ± 16      | 0.717   | 0.497   |
| Urea (mmol/L)                     | 7.66 ± 1.02     | 6.81 ± 1.25 | 6.87 ± 0.83  | 2.035   | 0.150   |
| Creatinine (μmol/L)               | 24 ± 4          | 24 ± 3      | 23 ± 3       | 0.279   | 0.759   |
| Cholesterol (mmol/L)              | 2.65 ± 0.50     | 2.67 ± 0.45 | 2.72 ± 0.48  | 0.050   | 0.951   |
| Triglyceride (mmol/L)             | 1.66 ± 0.63     | 1.51 ± 0.29 | 1.66 ± 0.30  | 0.390   | 0.681   |
| Blood glucose (mmol/L)            | 9.45 ± 1.33     | 7.76 ± 0.72** | 8.34 ± 0.99* | 6.795   | 0.004   |
| Total protein (g/L)               | 52.2 ± 2.6      | 52.9 ± 2.0  | 52.4 ± 1.6   | 0.289   | 0.751   |
| Albumin (g/L)                     | 32.6 ± 0.9      | 32.6 ± 1.2  | 32.1 ± 1.2   | 0.825   | 0.449   |

Subacute toxicity evaluations
Beginning on the third week of exposure to C-dots, the body weight of the rats in all groups significantly increased (Table 4). The difference in the body weight changes of the rats between the negative groups every week was insignificant (P > 0.05). The food intake and food utilization of the test groups were not significantly different between the negative groups (P > 0.05).

Body weight of rats was taken at different time points after C-dot treatment. Data were mean ± SD. Significant difference was analyzed by one-way ANOVA test.

To reveal any potential toxic effect of the C-dots on the treated rats, biochemical and hematological analyses were performed. The following key hematology markers were assessed at various time points (1, 3, 7, and 28 days): white blood cells, red blood cells, platelets, lymphocytes, neutral cells, other cells, hemoglobin, and hematocrit (HCT) (Figure 2). All above parameters in rats treated with different concentrations of C-dots at different time points appeared to be normal compared with the control groups. However, 7 days after exposure, the HCT of the low-dose C-dot-treated group showed a

### Table 4 Diversification of rat body weight

| Gender | Dose           | Number of rats | Initial weight (g) | First week (g) | Second week (g) | Third week (g) | Fourth week (g) |
|--------|----------------|----------------|--------------------|--------------|---------------|---------------|-----------------|
|        |                |                | F                  | p            | F             | p              | F               | p               |
| Female | Negative control | 8              | 193.9 ± 8.24       | 0.327        | 0.806         | 204.5 ± 9.4   | 222.6 ± 11.6    | 237.4 ± 16.3    | 0.177          | 0.911         |
|        | Low            | 8              | 191.2 ± 7.70       | 0.009        | 0.993         | 201.8 ± 3.6   | 220.0 ± 12.1    | 237.4 ± 13.4    | 0.279          | 0.780         |
|        | Middle         | 8              | 194.4 ± 7.01       | 0.074        | 0.944         | 203.4 ± 6.8   | 219.9 ± 11.0    | 234.8 ± 13.0    | 0.390          | 0.681         |
|        | High           | 8              | 1946.7 ± 7.71      | 0.007        | 0.933         | 204.1 ± 10.4  | 220.4 ± 12.1    | 231.9 ± 18.7    | 0.219          | 0.829         |
| Male   | Negative control | 8              | 207.9 ± 7.90       | 0.070        | 0.941         | 205.8 ± 9.6   | 208.1 ± 12.1    | 234.4 ± 18.4    | 0.383          | 0.626         |
|        | Low            | 8              | 210.2 ± 7.3        | 0.008        | 0.932         | 246.5 ± 7.8   | 302.1 ± 12.1    | 336.4 ± 17.8    | 0.273          | 0.765         |
|        | Middle         | 8              | 211.4 ± 8.8        | 0.100        | 0.910         | 245.9 ± 14.3  | 297.5 ± 16.8    | 336.0 ± 19.1    | 0.379          | 0.626         |
|        | High           | 8              | 205.0 ± 8.4        | 0.009        | 0.931         | 245.4 ± 11.4  | 308.5 ± 11.6    | 346.4 ± 15.6    | 0.383          | 0.626         |
Figure 2 Blood hematology analysis of rats treated with C-dots. The rats were treated with C-dots at doses of 0.2, 2, and 20 mg/kg BW in 1, 3, 7 and 28 days. (A) White blood cells, (B) red blood cells, (C) hemoglobin, (D) HCT, (E) platelets, (F) lymphocytes, (G) neutral cells, and (H) other cells.

Figure 3 Changes of the blood biochemical data of rats treated with C-dots. The rats were treated with C-dots at doses of 0.2, 2, and 20 mg/kg BW in 1, 3, 7, and 28 days. (A) GPT, (B) GOT, (C) urea, (D) cholesterol, (E) TG, (F) blood glucose, (G) Cr, (H) total protein, and (I) albumin.
significant difference compared with that of the normal control group ($P < 0.05$).

Subacute C-dot poisoning can cause changes in the following biochemical indices: GOT, GPT, urea, Cr, cholesterol, TG, blood glucose, total protein, and albumin (Figure 3). On the first day after exposure, the blood arsenic level in the high-dose group was obviously higher than in the control group ($P < 0.01$), and the TG levels significantly decreased ($P < 0.01$). Within 30 days after the first exposure, all biochemical parameters of the rats treated with different doses of C-dots at different time points appeared to be normal compared with the control groups. Although some of the biochemical and hematological parameters were statistically different between the test and negative control group, these differences were not biologically significant.

The organs of the rats injected with C-dots at the highest dose of 20 mg/kg BW were harvested for histopathological analysis. These organs included the heart, liver, spleen, stomach, kidneys, lungs, brain, stomach, intestines, ovaries, and testes. As shown in Figure 4, no obvious organ damage was noticed. Likewise, no apparent histopathological abnormality or lesion in the test groups was observed. The size and structure of the cardiac muscle fibers in the test group were uniform and normal. There was no steatosis, necrosis, or hydropic degeneration

Table 5 Diversification of rat major organ weight

| Gender   | Dose     | Body weight (g) | Liver  | Spleen | Kidney | Ovarian/testis |
|----------|----------|-----------------|--------|--------|--------|----------------|
|          |          | Wet weight (g)  | Liver/ body (%) | Wet weight (g) | Spleen/ body (%) | Wet weight (g) | Kidney/ body (%) | Wet weight (g) | Organs/ body (%) |
| Female   | Negative control | 235.9 ± 17.2 | 6.74 ± 0.66 | 2.86 ± 0.22 | 0.60 ± 0.07 | 0.26 ± 0.03 | 1.78 ± 0.14 | 0.75 ± 0.05 | 0.24 ± 0.07 | 0.10 ± 0.03 |
|          | Low      | 235.8 ± 12.8   | 6.92 ± 0.53 | 2.94 ± 0.20 | 0.59 ± 0.04 | 0.25 ± 0.02 | 1.70 ± 0.12 | 0.72 ± 0.03 | 0.27 ± 0.05 | 0.12 ± 0.02 |
|          | Middle   | 234.9 ± 13.9   | 6.61 ± 0.53 | 2.83 ± 0.30 | 0.59 ± 0.03 | 0.25 ± 0.01 | 1.71 ± 0.09 | 0.73 ± 0.05 | 0.25 ± 0.05 | 0.11 ± 0.02 |
|          | High     | 230.8 ± 20.6   | 6.67 ± 0.90 | 2.88 ± 0.22 | 0.56 ± 0.07 | 0.24 ± 0.02 | 1.76 ± 0.12 | 0.76 ± 0.03 | 0.26 ± 0.06 | 0.11 ± 0.02 |
| Male     | Negative control | 362.5 ± 22.7 | 12.52 ± 1.94 | 3.44 ± 0.34 | 0.91 ± 0.14 | 0.25 ± 0.04 | 2.79 ± 0.25 | 0.77 ± 0.05 | 3.13 ± 0.13 | 0.86 ± 0.03 |
|          | Low      | 352.9 ± 17.8   | 11.21 ± 1.05 | 3.18 ± 0.24 | 0.90 ± 0.08 | 0.25 ± 0.02 | 2.65 ± 0.23 | 0.75 ± 0.07 | 3.19 ± 0.16 | 0.90 ± 0.06 |
|          | Middle   | 354.1 ± 27.0   | 11.22 ± 1.02 | 3.18 ± 0.30 | 0.86 ± 0.10 | 0.24 ± 0.03 | 2.61 ± 0.16 | 0.74 ± 0.05 | 3.21 ± 0.18 | 0.91 ± 0.04 |
|          | High     | 362.1 ± 15.3   | 11.16 ± 0.91 | 3.08 ± 0.26 | 0.90 ± 0.72 | 0.25 ± 0.02 | 2.66 ± 0.16 | 0.73 ± 0.04 | 3.21 ± 0.19 | 0.89 ± 0.05 |
in the exposed hepatic sections. The structure of the liver lobule was normal, with few collagen fibers located in the portal area and central vein. The splenic capsule was complete, and the red and white pulps were clear. The lung structures were normal and no inflammation was found. In the sections of the kidneys, the glomerular structure was easily distinguished. No bleeding, ulcer, or abnormal differentiation was observed in the gastric mucosa.

No significant difference was found between the weights of the major organs (liver, spleen, kidney, ovaries, and testes) between the test groups (both female and male) and negative control group ($P > 0.05$), as shown in Table 5.

The liver, spleen, kidney, and ovary/testis of rats were separated and weighed. Data were mean ± SD. Significant difference was analyzed by one-way ANOVA test.

### Medullary micronucleus test

Table 6 shows that the micronucleus cell frequency (MCF) of hematopoietic cells in the mouse bone marrow and the polychromatic erythrocyte/normochromatic erythrocyte (PCE/NCE) were all within the normal range. The MCF results of the positive group were higher than that of the negative group ($P < 0.01$). All C-dot dosages did not induce micronucleus formation in the mouse cells.

Data were mean ± SD. ***$P < 0.001$ compared with that from the negative control. Significant difference was analyzed by the chi-square test.

### S. typhimurium mutagenicity (Ames) test

The results of the Ames test showed that no detectable mutagenicity was caused by the C-dots under the experimental conditions.
conditions, as shown in Table 7. Strains TA97, TA98, and TA102 were induced by dexon (50 μg/plate), whereas strain TA100 was treated with sodium azide (1.5 μg/plate) without the addition of the S-9 system. Strains TA97, TA98, and TA100 were induced by 2-acetylaminofluorene (5 μg/plate), whereas strain TA102 was treated with 8-di-hydroxyanthraquinone (50 μg/plate) when the S-9 system was added. Except for TA100, all strains were induced positively by the solvent dimethylsulfoxide with the S-9 system added. The number of colonies in each culture dish was scored after 48 h of cell culture. Data were mean ± SD.

Conclusion
In this work, photoluminescent C-dots with good stability, water solubility, and high dispersibility were successfully prepared. The toxicity of the prepared C-dots was then systematically evaluated. The results showed that the fluorescent C-dots at difference doses did not exert any significant toxic effect on rats and mice under the doses used in our experiments. No abnormality or lesion was observed in the major organs of rats treated with the C-dots. The C-dots also did not exhibit any gene toxicity. Thus, the as-prepared C-dots have good biocompatibility and potential use in in vivo molecular imaging and biolabeling, and others.

Additional file

Additional file 1: Supplementary data. A document showing the preparation/production of C-dots.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
KW and ZG participated in the animal experiment. GG, YW, and YW designed and participated in the animal experiments. GS synthesized the photoluminescent carbon dots evaluated in this research. DC participated in the design and the coordination of this study. All authors read and approved the final manuscript.

Acknowledgment
This work was supported by the National Natural Science Foundation of China (no. 811101169 and no. 20803040), Chinese 973 Project (2010CB933901), New Century Excellent Talent of Ministry of Education of China (NCET-08-0350), Special Infection Diseases Key Project of China (2010CB933901), New Century Excellent Talent of Ministry of Education of China.

Received: 2 January 2013 Accepted: 31 January 2013 Published: 8 March 2013

References
1. Yu SJ, Kang MW, Chang HC, Chen KM, Yu YC. Bright fluorescent nanodiamonds: no photobleaching and low cytotoxicity. J Am Chem Soc 2005, 127:17604.
2. Juzenas P, Chen W, Sun YP, Coelhox MAN, Generalov R, Generalov N, Christensen IL. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev 2008, 60:1600.
3. Peng H, Travas-Sejdic J. Simple aqueous solution route to luminescent carbogenic dots from carbohydrates. Chem Mater 2009, 21:5563.
4. Xu X, Ray R, Gu Y, Ploehn HJ, Gearheart L, Raker K, Scrivens WJ. Electrophoretic analysis and purification of fluorescent single-walled carbon nanotube fragments. J Am Chem Soc 2004, 126:12736.
5. Bottini M, Balasubramanian C, Dawson MI, Bergamaschi A, Bellucci S, Mustelin T. Isolation and characterization of fluorescent nanoparticles from pristine and oxidized electric arc-produced single-walled carbon nanotubes. J Phys Chem B 2006, 110:831.
6. Cao L, Wang X, Meziani MJ, Lu F, Wang H, Luo PG, Lin Y, Harruff BA, Veca LM, Murray D. Carbon dots for multiphoton bioimaging. J Am Chem Soc 2007, 129:13118.
7. Liu H, Ye T, Mao C. Fluorescent carbon nanoparticles derived from candle soot. Angew Chem Int Ed 2007, 46:6473.
8. Bourlinos AB, Stassinopoulos A, Anglos D, Zboril R, Karakassides M, Giannelis EP. Surface functionalized carbogenic quantum dots. Small 2008, 4:455.
9. Bourlinos AB, Stassinopoulos A, Anglos D, Zboril R, Georgakilas V, Giannelis EP. Photoluminescent carbogenic dots. Chem Mater 2008, 20:4539.
10. Zheng L, Chi Y, Dong Y, Lin J, Wang B. Electrochemiluminescence of water-soluble carbon nanocrystals released electrochemically from graphite. J Am Chem Soc 2009, 131:4564.
11. Pan X, Cui X, Li L. Synthesis of large, stable colloidal graphene quantum dots with tunable size. J Am Chem Soc 2010, 132:5944.
12. Wang X, Qu K, Xu B, Ren J, Qu Y. Microwave assisted one-step green synthesis of cell-permeable multicolor photoluminescent carbon dots without surface passivation reagents. J Mater Chem 2011, 21:2445.
13. Zhu H, Wang X, Li Y, Wang Z, Yang F, Yang X. Microwave synthesis of fluorescent carbon nanoparticles with electrochemiluminescence properties. Chem Commun 2009:5118.
14. Wang Q, Zheng H, Long Y, Zhang L, Cao M, Bai W. Microwave-hydrothermal synthesis of fluorescent carbon dots from graphite oxide. Carbon 2011, 49:3134–3140.
15. Liu R, Wu D, Liu S, Koym K, Knoll W, Li Q, I. An aqueous route to multicolor photoluminescent carbon dots using silica spheres as carriers. Angewandte Chemie 2009, 121:4668.
16. Yang ST, Cao L, Luo PG, Lu F, Wang X, Wang H, Meziani MJ, Liu Y, Qi G, Sun YP. Carbon dots for optical imaging in vivo. J Am Chem Soc 2009, 131:11308.
17. Sun YP, Wang X, Lu F, Cao L, Meziani MJ, Luo PG, Gu L, Veca LM. Doped carbon nanoparticles as a new platform for highly photoluminescent dots. J Phys Chem C 2008, 112:18295.
18. Sun YP, Zhou B, Lin Y, Wang W, Fernando KAS, Pathak P, Meziani MJ, Harruff BA, Wang X, Wang H. Quantum-sized carbon dots for bright and colorful photoluminescence. J Am Chem Soc 2006, 128:7756.
19. Zheng H, Chen GC, Song FM, Delouise LA, Lou ZY. The cytotoxicity of OPA-modified CdSe/ZnS core/shell quantum dots and its modulation by siblinin in human skin cells. J Biomed Nanotechnol 2011, 7:658–658.
20. Nirmala R, Park HM, Kalpana D, Kang HS, Navamathavan R, Lee YS, Kim HY. Bactericidal activity and in vitro cytotoxicity assessment of hydroxyapatite containing gold nanoparticles. J Biomed Nanotechnol 2011, 7:342–350.
21. Zuzana M, Alessandra R, Lise F, Maria D. Safety assessment of nanoparticles cytotoxicity and genotoxicity of metal nanoparticles in vitro. J Biomed Nanotechnol 2011, 7:20–21.
22. Painuliy D, Bhatt A, Krishnan VK. Mercaptoethanol capped cds quantum dots and CdSe/ZnS core/shell: synthesis, characterization and cytotoxicity evaluation. J Biomed Nanotechnol 2013, 9:257–266.
23. Yang ST, Wang X, Wang H, Lu F, Luo PG, Cao L, Meziani MJ, Liu JH, Liu Y, Chen M, Huang YP. Sun YP. Carbon dots as nontoxic and high-performance fluorescence imaging agents. J Phys Chem C 2009, 113:18110.
24. Christensen IL, Sun YP, Juzenas P. Carbon dots as antioxidants and prooxidants. J Biomed Nanotechnol 2011, 7:667.
25. Hardman R: A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 2006, 114:165.

26. Wang K, Ruan J, Song H, Zhang J, Wo Y, Guo S, Cui D: Biocompatibility of graphene oxide. Nanoscale Res Lett 2011, 6:1.

27. Lacerda L, Bianco A, Prato M, Kostarelos K: Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev 2006, 58:1460.

28. Donaldson K, Atken R, Tran L, Stone V, Duffin R, Forrest G, Alexander A: Carbon nanotubes: a review of their properties in relation to pulmonary toxicity and workplace safety. Toxicol Sci 2006, 92:5.

29. Lewinski N, Colvin V, Drezek R: Cytotoxicity of nanoparticles. Small 2008, 4:26.

30. Allon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML: Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 2009, 61:457.

31. Shvedova A, Kisin E, Porter D, Schulte P, Kagan V, Fadeel B, Castranova V: Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: two faces of Janus? Pharmacol Ther 2009, 121:192.

32. Singh N, Manish B, Jenkins GS, Griffiths SM, Williams PM, Maffei TGG, Wright CJ, Doak SH: NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 2009, 30:3891.

33. Firme CP, Bandaru PR: Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine: Nanotechnology, Biology and Medicine 2010, 6:245.

34. Kokonij I, Sawar H, Moussa F: Toxicity studies of fullerenes and derivatives. Bio-Applications of Nanoparticles 2007, 620:168–180.

do:10.1186/1556-276X-8-122
Cite this article as: Wang et al: Systematic safety evaluation on photoluminescent carbon dots. Nanoscale Research Letters 2013 8:122.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com